Business Description
Nxera Pharma Co Ltd
ISIN : JP3431300007
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.72 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 1.03 | |||||
Debt-to-EBITDA | 66.8 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.91 | |||||
Beneish M-Score | -1.53 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 45.22 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.18 | |||||
9-Day RSI | 47.43 | |||||
14-Day RSI | 45.34 | |||||
6-1 Month Momentum % | -21.39 | |||||
12-1 Month Momentum % | -21.7 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.11 | |||||
Quick Ratio | 3.96 | |||||
Cash Ratio | 3.29 | |||||
Days Inventory | 142.43 | |||||
Days Sales Outstanding | 56.35 | |||||
Days Payable | 169.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | -39.75 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.27 | |||||
Operating Margin % | -14.96 | |||||
Net Margin % | -12.68 | |||||
FCF Margin % | 5.82 | |||||
ROE % | -5.76 | |||||
ROA % | -2.58 | |||||
ROIC % | -3.52 | |||||
3-Year ROIIC % | -10.56 | |||||
ROC (Joel Greenblatt) % | -25.41 | |||||
ROCE % | -2.23 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 26.63 | |||||
PS Ratio | 3.59 | |||||
PB Ratio | 1.56 | |||||
Price-to-Free-Cash-Flow | 66.43 | |||||
Price-to-Operating-Cash-Flow | 45.47 | |||||
EV-to-EBIT | -43.96 | |||||
EV-to-EBITDA | 119.77 | |||||
EV-to-Revenue | 4.35 | |||||
EV-to-FCF | 74.9 | |||||
Price-to-Projected-FCF | 1.23 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Earnings Yield (Greenblatt) % | -2.27 | |||||
FCF Yield % | 1.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nxera Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 29,275 | ||
EPS (TTM) (円) | -41.22 | ||
Beta | 0.31 | ||
Volatility % | 31.23 | ||
14-Day RSI | 45.34 | ||
14-Day ATR (円) | 40.231815 | ||
20-Day SMA (円) | 1192.7 | ||
12-1 Month Momentum % | -21.7 | ||
52-Week Range (円) | 1125 - 1826 | ||
Shares Outstanding (Mil) | 89.9 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nxera Pharma Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nxera Pharma Co Ltd Stock Events
Event | Date | Price(円) | ||
---|---|---|---|---|
No Event Data |
Nxera Pharma Co Ltd Frequently Asked Questions
What is Nxera Pharma Co Ltd(TSE:4565)'s stock price today?
When is next earnings date of Nxera Pharma Co Ltd(TSE:4565)?
Does Nxera Pharma Co Ltd(TSE:4565) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |